Analystreport

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) had its price target lowered by analysts at SVB Leerink LLC from $48.00 to $45.00. They now have an "outperform" rating

Dicerna Pharmaceuticals, Inc.  (DRNA) 
Last dicerna pharmaceuticals, inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dicerna.com